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Abstract
Background Reconstruction of the distal femur after re-
section for malignant bone tumors in skeletally immature
children is challenging. The use of megaprostheses has
become increasingly popular in this patient group since the
introduction of custom-made, expandable devices that do
not require surgery for lengthening, such as the Repiph-
ysis1 Limb Salvage System. Early reports on the device
were positive but more recently, a high complication rate
and associated bone loss have been reported.
Questions/purposes We asked: (1) what are the clinical
outcomes using the Musculoskeletal Tumor Society
(MSTS) scoring system after 5-year minimum followup in
patients treated with this prosthesis at one center; (2) what
are the problems and complications associated with the
lengthening procedures of this implant; and (3) what are
the specific concerns associated with revision of this
implant?
Methods At our institute, between 2002 and 2007, the
Repiphysis1 expandable prosthesis was implanted in 15
children (mean age, 8 years; range, 6–11 years) after distal
femoral resection for malignant bone tumors. During this
time, the general indication for use of this implant was
resection of the distal femur for localized malignant bone
tumors in pediatric patients. Alternative techniques used
for this indication were modular prosthetic reconstruction,
massive (osteoarticular or intercalary) allograft recon-
struction, or rotationplasty. Age and tumor extension were
the main factors to decide on the surgical indication. Of the
15 patients who had this prosthesis implanted during re-
construction surgery, five died with the implant in situ or
underwent amputation before 5 years followup and the
remaining 10 were evaluated at a minimum of 5 years
(mean, 104 months; range, 78–140 months). No patients
were lost to followup. These 10 patients were long-term
survivors and underwent the lengthening program. They
were included in our study analysis. The first seven
lengthening procedures were attempted in an outpatient
setting; however, owing to pain and burning sensations
experienced by the patients, the procedures failed to
achieve the desired lengthening. Therefore, other proce-
dures were performed with the patients under general
anesthesia. We reviewed clinical data at index surgery for
all 15 patients. We further analyzed the lengthening pro-
cedures, implant survival, radiographic and functional
results, for the 10 long-term survivors. Functional results
were assessed according to the MSTS scoring system.
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Complications were classified according to the Interna-
tional Society of Limb Salvage (ISOLS) classification
system.
Results Nine of the 10 survivors underwent revision of
the implant for mechanical failure. They had a mean MSTS
score of 64% (range, 47%–87%) before revision surgery.
At final followup the 10 long-term surviving patients had
an average MSTS score of 81% (range, 53%–97%). In
total, we obtained an average lengthening of 39 mm per
patient (range, 17–67 mm). Exact expansion of the implant
was unpredictable and difficult to control. Nine of 10 of the
long-term surviving patients underwent revision surgery of
the prosthesis—eight for implant breakage and one for
stem loosening. At revision surgery, six patients had an-
other type of expandable prosthesis implanted and three
had an adult-type megaprosthesis implanted. In five cases,
segmental bone grafts were used during revision surgery to
compensate for loss of bone stock.
Conclusions We could not comfortably expand the
Repiphysis1 prosthesis in an outpatient setting because of
pain experienced by the patients during the lengthening
procedures. Furthermore, use of the prosthesis was asso-
ciated with frequent failures related to implant breakage
and stem loosening. Revisions of these procedures were
complex and difficult. We no longer use this prosthesis and
caution others against the use of this particular prosthesis
design.
Level of Evidence Level IV, therapeutic study.
Introduction
Limb salvage after tumor resection in a skeletally immature
child, particularly in the lower limb, is challenging. The
primary goal of surgical treatment is complete removal of
the tumor with adequate margins. Reconstruction is par-
ticularly difficult because of the relatively small anatomic
size, reduced growth in the surgically treated limb resulting
in a potential limb-length discrepancy, and the high func-
tional and mechanical demands of young, active patients
[1, 14, 21]. Expandable prostheses have been developed to
address the problem of limb-length discrepancy, compen-
sating for lost growth potential and maintaining good
function of the treated joint [5, 19, 24, 25].
The introduction of expandable prostheses that can be
lengthened without the need for invasive surgery or general
anesthesia made this type of reconstruction increasingly
popular. The Repiphysis1 prosthesis was the first expand-
able endoprosthesis commercially availableworldwide,with
a lengthening mechanism that did not require any surgery.
The device was introduced by Wright Medical Technology
(Arlington, TN, USA) and received approval from the FDA
in 2002. The Repiphysis1 Limb Salvage System was later
acquired by MicroPort Orthopedics Inc (Arlington, TN,
USA), which is the current manufacturer of the implant [20].
Initially, there were positive reports on short-term results of
the implant [6, 11, 17, 26], but there have been increasing
concerns regarding high complication rates and poor func-
tion at longer followup [3, 4, 16, 22].
We therefore analyzed our experience with the Repi-
physis1 prosthesis in 10 patients younger than 12 years,
who had survived 5 or more years after treatment for a
malignant bone tumor of the distal femur. We asked (1)
what are the clinical outcomes using the Musculoskeletal
Tumor Society (MSTS) scoring system after 5-year mini-
mum followup in patients treated with this expandable
prosthesis; (2) what are the problems and complications
associated with the lengthening procedures of the implant;
and (3) what are the specific concerns associated with re-
vision of the implant?
Patients and Methods
We performed retrospective clinical and radiographic
evaluations of all pediatric patients (younger than 12 years)
who underwent reconstruction of the distal femur with the
Repiphysis1 custom-made expandable prosthesis after re-
section, between 2002 and 2007 at one institute, for a
malignant bone tumor. The patients in this study were
identified from an observational prospective study.
Between 2002 and 2007 at our institution, the Repiph-
ysis1 custom-made, expandable prosthesis was implanted
in 15 patients who underwent resection of the distal femur
for a malignant bone tumor. The series included nine male
and six female patients, with a mean age of 8 years (range,
6–11 years). The diagnosis was high-grade osteosarcoma in
14 patients and Ewing’s sarcoma in one. All patients re-
ceived pre- and postoperative chemotherapy according to
well-established protocols [9, 10].
During that period, our general indications for using this
implant were resection of the distal femur for localized
malignant bone tumors in pediatric patients. During the
same time, for similar indications, we used an adult-type of
modular prosthesis in five patients (all 12 years old), a
modular megaprosthesis with a smooth tibial stem in eight
patients (between 9 and 12 years old), one intercalary re-
construction after resection through the epiphysis, four
rotationplasties (in patients younger than 7 years or with
very large tumors), two other types of expandable pros-
theses (mechanical lengthening through a small incision),
and two osteoarticular allografts. Age and tumor extension
were the main factors leading to the decision to use this
expandable implant. In general, we opted for the
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expandable prosthesis when patients were between 7 and
12 years old, had an expected potential limb length dis-
crepancy of at least 4 cm, good clinical and radiographic
response to preoperative chemotherapy, possibility to save
the primary neurovascular bundle, and with at least 8 cm of
longitudinal tumor extension from the joint line. This
might have resulted in a selection bias compared with other
approaches.
One patient died because of drug toxicity during che-
motherapy. Two patients had a local recurrence and
underwent an above knee amputation at 6 and 19 months
after the index surgery. Each died of diffuse disease at 11
and 28 months followup, respectively. Three other patients
had lung metastases during followup. Two of them died at
20 and 28 months after the primary surgery (one of the
patients had undergone implant removal at 8 months fol-
lowup because of a postoperative infection). None of these
patients underwent the lengthening program and their
functional results, complications, or revision procedures
are not included in this study. The other patient who had
lung metastasis is alive and in complete remission 85
months after thoracotomy and wedge resection of the lung
nodules. Ten long-term surviving patients underwent the
lengthening program and we evaluated implant survival
and functional outcome for these patients only. Mean fol-
lowup of this group of patients was 104 months (range,
78–140 months).
The Repiphysis1 custom-made, noninvasive expand-
able prosthesis uses a telescopic lengthening mechanism
composed of a titanium tube embedded in a polyethylene
housing cylinder (Fig. 1). The energy to lengthen the
implant is stored in a compressed spring inside the tita-
nium tube. The end of the titanium tube is flared and
engages in the polyethylene cylinder, locking it into place.
When lengthening is required, an external electromagnetic
field is generated by a coil, which is placed circumferen-
tially to the extremity at the level of the implant. The coil
heats and softens the polyethylene cylinder, allowing for
the titanium tube to disengage from its housing. At this
stage, the compressed spring partially releases and ex-
pands, sliding the titanium tube out of the polyethylene
cylinder, lengthening the implant. Once the flared part of
the tube reaches a new and cooler portion of polyethylene,
it is locked back in place, limiting further expansion [18,
20, 26]. According to the manufacturer [20], it takes ap-
proximately 20 seconds to obtain 0.8-mm expansion of the
prosthesis, but this is variable and further lengthenings are
estimated in a table in the manufacturer’s instructions. It is
not possible to reverse the lengthening obtained with each
expansion. It is recommended that the procedure be per-
formed under fluoroscopic guidance. Lengthening of the
device can be performed without anesthesia or sedation in
an outpatient setting according to the manufacturer [20]
and Ness et al. [18]. The maximum expansion capacity of
the prosthesis depends on the length of the prosthesis, and
indirectly, on the length of the resected bone. According to
oncologic principles, the resection level was at least 2 cm
proximal to the tumor extension, as measured on preop-
erative MR images. The custom-designed prosthesis was
usually between 0.5 and 1 cm longer than the planned
distal femoral resection segment to gain some initial
lengthening at the time of reconstruction. In this series the
prosthesis varied in length from 126 mm to 202 mm, with
a lengthening capacity ranging from 3.5 cm to 11 cm.
All study patients underwent distal femur resections for
bone sarcomas, according to oncologic principles, and
wide surgical margins were achieved in all cases. Cement
was used to fix the stem of the femoral component in all
but one patient. In this patient’s reconstruction surgery, a
plasma-coated, uncemented stem was inserted in the
femoral canal; with the records available in this retro-
spective study, we were unable to ascertain why this
approach was chosen for this patient. In all cases, the
proximal tibia was shaved minimally and the stem was
Fig. 1A–B (A) The Repiphysis1 prosthesis and (B) the generator of
the external electromagnetic field are shown.
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inserted in a press-fit manner to cause the least possible
damage to the proximal tibial growth plate, as it maintains
growth at the level the proximal tibial physis [8, 17].
Postoperatively, the patients were instructed to immedi-
ately bear weight as tolerated but to refrain from impact
activities.
We retrospectively studied the medical records for
clinical details (including age, sex, weight, tumor site, di-
agnosis, and resection length), and implant characteristics
(implant length, stem diameter, stem length, expansion
capacity). Furthermore, we analyzed clinical, radiographic,
and oncologic outcomes. Functional results were assessed
in patients who had survived their disease at final followup,
according to the MSTS scoring system [7]. We focused
specifically on implant survival, complications, limb-
length discrepancy, lengthening procedures, and revision
surgery. Complications were classified according to the
International Society of Limb Salvage (ISOLS) classifica-
tion system [13].
Results
Nine of 10 patients underwent revision of their prosthesis
for mechanical failure. Before revision these nine patients
had a mean MSTS score of 64% (range, 47%–87%). At
final followup, the 10 long-term surviving patients had an
average MSTS score of 81% (range, 53%–97%). We then
focused our review of patient data on implant survival and
revision surgery (Table 1).
The first seven lengthening procedures (in three pa-
tients) were attempted in an outpatient setting with the
patients receiving no anesthesia. However, these proce-
dures were unsatisfactory because of the difficulties for
patients who reported sudden pain and burning sensations
during lengthening. Moreover, it became clear that without
complete muscle relaxation, only limited lengthening was
achievable. The following 39 lengthening procedures were
performed with the patients under general anesthesia on a
day-hospital basis (Fig. 2). In all procedures, the
manufacturer guidelines for the prosthesis were observed
and instructions for the duration of each lengthening ses-
sion were strictly followed. A total lengthening of 390 mm
was obtained in 46 lengthening sessions which means an
average lengthening of 39 mm per patient (range, 17–67
mm) (Table 2). Although the procedures were performed
in a standardized manner, great variability of expansion
ranging from 0 to 20 mm was observed. Postlengthening
inflammation of the thigh with pain, stiffness, febrile re-
sponses, and radiographic appearance of a radiolucent layer
around the prosthetic body (Fig. 3) were observed in six
patients and became a consistent set of findings after their
third lengthening procedure. Their temperature varied
Table 1. Patient data
Patient
number
Age,
(years)/sex
Oncologic
outcome
Followup
(months)
Revision
surgery/explantation
Repiphysis
Time to revision
(months)
Reason for
revision
MSTS at revision
surgery (%)
1 9/M CDF 140 Expandable 49 Breakage 47
2 11/M DOD 20
3 8/F DOD 11 AKA LR
4 9/F CDF 126 Adult type 79 Breakage 47
5 8/M CDF 101 Expandable 55 Loosening 87
6 11/M DOD 28 AKA LR
7 8/M CDF 114 Expandable, bone 67 Breakage 77
8 7/M CDF 110 Expandable, bone 48 Breakage 63
9 9/F NED 100 Adult type, bone 71 Breakage 77
10 7/F CDF 96
11 6/M CDF 96 Expandable 61 Breakage 50
12 9/M DTOX 2
13 9/M DOD 28 Cement spacer 8 Infection
14 8/F CDF 81 Adult type, bone 56 Breakage 57
15 7/F CDF 78 Expandable, bone 76 Breakage 73
CDF = continuously disease free; NED = no evidence of disease; DTOX = dead due to chemotherapy toxicity; DOD = dead of disease;
Expandable = revision with another type of expandable prosthesis; Adult type = revision with a modular conventional megaprosthesis; AKA =
above knee amputation; LR = local recurrence; bone = segmental massive bone allograft; MSTS = Musculoskeletal Tumor Society functional
score.
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between 38 and 39 Celsius and disappeared sponta-
neously within 3 days without antibiotic treatment.
Nine patients had clinical and radiographic signs of
implant failure (metallic debris in the soft tissues, pro-
gressive stem loosening, breakage of the spring, or implant
instability) and underwent complete revision of the primary
implant at a mean of 62 months (range, 48–79 months)
after the index procedure. In all but one case, the femoral
stem was revised with a noncemented stem, which fits ei-
ther an expandable or modular adult-type prosthesis of the
implant system we have most experience with in our de-
partment. In the remaining case, a custom-made
expandable prosthesis of a different system was manufac-
tured to fit a well-fixed cemented stem from the
Repiphysis1 implant.
The most common cause of revision was spring break-
age (eight patients [89%]), an ISOLS type 3A
complication. A consistent finding during revision surgery
was the presence of extensive metallosis with a dark
greenish-gray pseudocapsule surrounding the prosthesis
(Fig. 4). One patient underwent revision surgery for aseptic
femoral stem loosening after 55 months, which is consid-
ered an ISOLS type 2B complication. In five cases during
revision surgery, a segmental allograft was used around the
residual host bone-stem interface to compensate for lost
bone stock in the short residual proximal femur segment
and to improve the femoral stem fixation (Fig. 5).
The five male patients who needed revision surgery for
implant failure were still skeletally immature (11–13 years
old) at the time of the revision surgery. Their implants were
revised with other types of expandable megaprostheses
(Fig. 6). Four had their implants revised to an expandable
prosthesis that can be lengthened through a small incision,
and one had a prosthesis implanted that can be lengthened
without surgery through application of an electromagnetic
field. Three of these patients required further implant
Fig. 2A–C (A) A plain radiograph of the Repiphysis1 distal femoral prosthesis before lengthening is shown. (B) Application of the external
electromagnetic field with the patient under general anesthesia and (C) fluoroscopic control of the lengthening procedure are shown.
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revision and their final limb length discrepancy ranged
from 1.5 to 2.5 cm. Three female patients (13–15 years old
at revision surgery) underwent revision surgery with im-
plantation of an adult-type megaprosthesis and had a final
limb length discrepancy ranging from 0 to 3.5 cm. Another
female patient (13 years old) with 5-cm limb shortening at
the time of revision surgery had implantation of a mini-
invasive expandable prosthesis. In one patient, a con-
tralateral epiphysiodesis of the distal femur and proximal
tibia was performed to avoid progression of the limb length
discrepancy.
Discussion
Limb-salvage surgery in skeletally immature children is a
challenging problem for orthopaedic surgeons because of the
need to create a functional and durable reconstruction,
minimize postsurgical complications, and address the
problem of potential limb length discrepancy [24]. The in-
troduction of less-invasive expandable prostheses is
purported to allow for implant expansion without further
surgical interventions and without use of general anesthesia,
making this type of reconstruction increasingly popular in
the treatment of skeletally immature childrenwithmalignant
bone tumors of the extremities [6, 11, 12, 15, 17, 26, 27].
However, we found that use of a particular expandable
prosthesis was associated with many complications, result-
ing in failure of the prosthesis, inability to achieve
Table 2. Followup data for the patients
Patient
number
Age
(years)/
sex
Total
lengthening
Revision of
Repiphysis1
Further revisions (months from
Repiphysis1 revision)
Final limb length
discrepancy
MSTS at
final followup
(months)
1 9/M 17 mm Expandable Adult type (95) 1.5 cm 16
2 11/M*
3 8/F*
4 9/F 31 mm Adult type 3 cm 26
5 8/M 48 mm Expandable DAIR for infection (9) 0 cm 27
6 11/M*
7 8/M 43 mm Expandable, bone 1.5 cm 23
8 7/M 67 mm Expandable, bone Expandable (26), adult type (62) 2 cm (EPD) 22
9 9/F 31 mm Adult type, bone 1 cm 26
10 7/F 23 mm 3.5 cm
11 6/M 40 mm Noninvasive expand 2.5 cm 26
12 9/M*
13 9/M* Cement spacer
14 8/F 50 mm Adult type, bone 0 cm 29
15 7/F 40 mm Expandable, bone Expandable 3 cm 23
Expandable = mini-invasive mechanically expandable prosthesis; Noninvasive expand = noninvasive expandable prosthesis; bone = segmental
massive bone allograft; DAIR = de´bridement, antibiotics, and implant retention; EPD = epiphysiodesis; MSTS = Musculoskeletal Tumor
Society; *= did not undergo lengthening.
Fig. 3 A plain radiograph shows an inflammatory reaction, 24 hours
after a lengthening procedure. The patient presented with thigh pain,
fever, and swelling around the implant. A radiolucency is visible
around the prosthetic body. The symptoms regressed spontaneously in
the following 48 hours.
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lengthening, and the need for surgical interventions and
revisions.
There are limitations to our study. Five of our patients
died within short followup, so only 10 patients are included
in our study. However, findings from the 10 patients were
sufficiently concerning to lead us to recommend against the
use of the Repiphysis1 prosthesis. Other limitations in-
cluded possible selection bias of cases as there are several
reconstructive options for the specific reconstruction site in
the age group of our patients, all with different surgical
techniques, possible complications, rehabilitation pro-
grams, costs, and functional goals.
Our series confirms the tendency that with longer fol-
lowup, the functional results deteriorate, owing to
mechanical failure. However, the improved MSTS scores
at final followup (on average 81%), compared with scores
at revision (average, 64%), show that complex revision
surgery can restore function. Our study included 10 pa-
tients with a mean age of 8 years and a minimum followup
of 5 years (mean of nearly 9 years). To our knowledge, this
study presents the longest followup of the Repiphysis1
implant published to date. The Repiphysis1 expandable
prosthesis was the first noninvasive expandable endopros-
thesis commercially available. Originally called the Phenix
prosthesis (Phenix Medical, Paris, France), it has been used
in Europe since the early 1990s and in the United States
since the late 1990s [23]. Early reports showed promising
preliminary results [11, 17, 26], with good-to-excellent
function and a relatively low complication rate. MSTS
scores in the early series with relatively short followup
varied from 81.7% to 90% [2, 11, 17, 18, 22], but in the
only previous series with an average followup of more than
6 years, the final MSTS score was on average 67% [4]
(Table 3).
With respect to lengthening of the device, our study
revealed a complication of the prosthesis that to our
knowledge has not been previously reported. The Repiph-
ysis1 expandable prosthesis failed to expand for us as
stated by the manufacturer, therefore only partially main-
taining the noninvasiveness. Owing to pain and burning
sensations the patients felt around the implant during the
lengthening procedures, these had to be performed with the
patients receiving general anesthesia. This has not been
reported in previous studies of this implant. Wilkins and
Souberain [26] mentioned very mild discomfort during the
lengthening procedures which could be managed with oral
analgesics. Patient age could partially explain the diffi-
culties in pain management with our patients. Our patients
were younger, with a mean age of 8 years at index surgery,
whereas in other series the patients were older than 10
years [2, 4, 11, 18, 22]. Furthermore, the amount of
lengthening was unpredictable and difficult to control. We
Fig. 4A–C (A) The radiograph shows signs of implant failure
including metallic debris in the soft tissues and breakage of the
spring. (B) The explanted prosthesis shows the periprosthetic
membrane with extensive metallosis and a dark greenish-gray
pseudocapsule. (C) The radiograph shows the removed implant at
revision surgery.
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performed 46 expansions in 10 patients, with an average of
8.4 mm per expansion. However, we observed gradual
reduction of lengthening capacity. Generally, after the first
three lengthening procedures of each prosthesis, the same
exposure time to the electromagnetic field led to less
lengthening. This might be related partially to the com-
pressed spring, which as it gradually gets released, loses
stored energy and expansion capacity. In addition, the in-
creasing resistance of a thick fibrotic tissue around the
implant, as seen in all revision surgeries, might influence
the lengthening capacity. Although the problem of metal-
losis and periprosthetic fibrosis has been reported [3, 4], the
difficulties controlling the amount of lengthening has not
been addressed. Gitelis et al. [11] reported one case of
failure to lengthen. Another potential disadvantage of this
implant is that there is no possibility to reverse the
lengthening achieved in case of overlengthening. We have
not experienced overlengthening in our patients, but there
is a potential risk for nerve damage through stretching if
this happens accidentally, which cannot be resolved easily
by shortening the implant.
Nine of 10 long-surviving patients underwent revision
surgery of the implant, all but one because of mechanical
failure of the implant. All revision surgeries were
Fig. 5A–I The intraoperative photographs show (A) preparation of
the segmental cortical allograft; (B) application of the allograft to the
host bone; (C) preparation of the stem wings distally in the segmental
cortical allograft; (D) stem introduction; (E) the distal part of the stem
with a thin mantle of cement, just before complete introduction; and
(F) final stem placement. The plain radiographs show (G) the
prosthesis before revision, (H) immediately postoperative, and (I) 40
months after revision surgery.
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performed between 4 and 7 years after implantation of the
prosthesis. The relatively early failures, before obtaining
complete lengthening, and generally before the patients
reached skeletal maturity, led to the need for revision with
a second expandable implant in six patients. It was possible
to revise the implant with an adult-type megaprosthesis in
only three female patients. The most common complica-
tions of the Repiphysis1 expandable implant have been
reported [3, 4, 16, 22]. Infection, spring breakage, aseptic
loosening, and fracture are well-recognized problems that
often lead to revision of the implant, and with longer fol-
lowup the percentage of revision surgeries seems to
increase. In our study, one implant was removed for early
postoperative infection and one implant was revised be-
cause of aseptic loosening. However, the most frequent
reason for revision was prosthetic failure attributable to
spring breakage (eight cases). Younger patient age and
longer followup in our current series compared with pre-
vious studies [2, 11, 17, 22] might have influenced the
results. Longer followup obviously exposes the implant to
more risks of failure. Younger age at index surgery could
influence the results through less compliance by the patient
and a relatively more pronounced change of body weight
and length. In addition, the biologic properties of bone
(such as elasticity, bone turnover, tendency for stress
shielding) are age dependent.
Cipriano et al. [4] stressed that extensive loss of bone
stock in the metadiaphyseal area was frequent and an im-
portant complication of the implant. The bone loss might
be attributable to extensive stress shielding of a cemented
stem in young patients with high bone remodeling. Metal
and polyethylene debris associated with high wear of the
Fig. 6A–D Sequential radiographs show (A) spring breakage of the Repiphysis1 prosthesis in 2008, followed by (B) revision surgery in 2010
with another type of expandable prosthesis, and radiographic controls after expanding the new prosthesis in (C) 2011 and (D) 2012.
Table 3. Summary of literature on outcomes of Repiphysis1 expandable prosthesis
Study Number of patients Followup (months) Cases revised (%) MSTS scores (%)
Wilkins & Souberain [26] 6 14 2/7 (29) NA
Neel et al. [17] 15 21.5 8/15 (53) 90
Gitelis et al. [11] 16 24.8 7/16 (44) 83.5
Beebe et al. [2] 12 38 7/12 (58) 81.7
Ness et al. [18] 13 46 6/13 (46) 73
Saghieh et al. [22] 12 61.7 7/12 (58) 90
Cipriano et al. [4] 10 72 8/10 (80) 67
Current study 10 104 9/10 (90) 81
MSTS = Musculoskeletal Tumor Society; NA = Not available.
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implant material might play a role in osteolytic processes
resulting in stem loosening and bone loss, both of which
increase the complexity of future operations. The
manufacturer of the Repiphysis1 implant suggests using
cement for the femoral stem fixation [20] which can lead to
more bone loss and the need for revision surgery. A well-
fixed stem could be left in place and used to attach another
implant, but this requires a custom-made adapter with the
Repiphysis1, thereby increasing the costs and complexity
of this relatively expensive implant system. In the series of
Cipriano et al. [4], two patients had to be undergo revision
surgery with a total femoral replacement owing to exten-
sive bone loss. We noticed similar loss of bone stock. We
could avoid implanting total femoral replacements, but we
used segmental allogafts in five cases to achieve good
proximal stem fixation of the revision implant and avoid
use of an adapter component or total femoral implant.
In our series, the Repiphysis1 prosthesis was associated
with frequent failures and problems during lengthening
procedures. Although lengthenings in our patients were in
the range of values reported by others [2, 4, 11, 22], the
majority of our procedures were painful for the patients if
anesthesia was not used. We also were not able to control
the amount of expansion during each lengthening proce-
dure and the amount of expansion tended to decrease with
time. We confirm that the implant showed unacceptable
fragility and mechanical failure before obtaining the
complete limb lengthening expected, with the need for
revision with a second expandable implant. Furthermore,
revision was a complex and difficult procedure although
the functional results for our patients were improved. We
have not used the Repiphysis1 prosthesis since 2008 and
have been using another type of expandable implant. Based
on our findings and those of others [3, 4, 16], we caution
against the use of this particular prosthesis.
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